Thirty percent of epilepsies do not respond to currently available drug treatments. Over 20 million worldwide have pharmacoresistant epilepsies. There is a pressing need for new, effective anti-epilepsy drugs, and the use of cannabis and cannabinoid medicines is promising.
The mechanism by which cannabinoids inhibit seizure activity likely extends beyond interaction with the cannabinoid receptor CB1 to other receptors systems within the body.
Molecules to target seizure disorders
Recently, CBD molecules have become popular among patients with seizure disorders. A small percentage of seizure sufferers don’t respond to CBD but would likely respond to CBDV. However, high CBDV strains are quite rare in the United States, and few patients have access to them. As far as the terpenes go, myrcene is probably beneficial because of its synergistic properties as well as linalool due to its calming effect.
Dosing for seizure disorders
Dosing guidance for the use of cannabinoids for seizure disorders depends on the type of disorder and the kind of cannabinoid being used. Consultation with a physician with a solid understanding of cannabinoid medicine is highly recommended to help determine appropriate dosage guidelines because of the risk that the use of specific cannabinoids pose toward increased seizure activity.
Methods of ingestion
Sublingual and buccal administration is recommended to conventional oral use since swallowed medication may be less effective due to the way cannabinoids are metabolized in the liver.
In adults, vaporized cannabis is commonly used by patients with seizure disorders.